{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:54:12Z","timestamp":1775069652122,"version":"3.50.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Benzodiazepines (BZDs) are central nervous system depressants that are prescribed to prevent seizures, manage anxiety, or help sleep. When misused, BZDs can lead to addiction and sometimes cause death. Measurement of BZDs in urine is used to identify their use, especially in pain management settings. LC-MS\/MS is preferred for these measurements because of its high sensitivity and specificity. Here, we report an LC-MS\/MS assay for measuring 7 BZDs and metabolites in urine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Urine sample was incubated at 60 \u00b0C for 30 min after addition of internal standards and a \u03b2-glucuronidase solution. After centrifugation, the supernatant was diluted with methanol and water before being injected onto a C18 analytical column in an LC-MS\/MS system for quantification. The analytical time between injections was 4.35 min. The analytes included 7-aminoclonazepam, \u03b1-hydroxyalprazolam, \u03b1-hydroxytriazolam, oxazepam, lorazepam, nordiazepam, and temazepam.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The lower limit of quantification ranged from 30 ng\/mL to 50 ng\/mL with an analytical recovery &amp;gt;80% for all 7 analytes. Total CV was &amp;lt;10% for all analytes (3 concentration levels of 100, 2500, and 5000 ng\/mL; n = 30 each). This method had 100% agreement with a GC-MS method offered by an independent laboratory for negative urine samples. For the positive urine samples, this method showed a strong correlation (R &amp;gt; 0.96) with the GC-MS method.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The LC-MS\/MS assay allows accurate and precise measurement of 7 BZDs and metabolites in a single analytical run with a short analytical run time and broad measuring ranges.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1373\/jalm.2018.026658","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T17:07:40Z","timestamp":1540487260000},"page":"397-407","source":"Crossref","is-referenced-by-count":2,"title":["Quantitation of Benzodiazepines and Metabolites in Urine by Liquid Chromatography\u2013Tandem Mass Spectrometry"],"prefix":"10.1093","volume":"3","author":[{"given":"Yu Zi","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dustin R","family":"Bunch","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Lembright","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihe","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Cleveland Clinic, Cleveland, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,11,1]]},"reference":[{"key":"2022020118392880900_B1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0740-5472(91)90027-8","article-title":"History of benzodiazepine dependence","volume":"8","author":"Lader","year":"1991","journal-title":"J Subst Abuse Treat"},{"key":"2022020118392880900_B2","author":"Benzodiazepines","year":"2013"},{"key":"2022020118392880900_B3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","article-title":"Polydrug abuse: a review of opioid and benzodiazepine combination use","volume":"125","author":"Jones","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"2022020118392880900_B4","first-page":"393","article-title":"Benzodiazepine abuse and dependence: misconceptions and facts","volume":"31","author":"Farnsworth","year":"1990","journal-title":"J Fam Pract"},{"key":"2022020118392880900_B5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.forsciint.2016.09.006","article-title":"Blood concentrations of new designer benzodiazepines in forensic cases","volume":"268","author":"Hoiseth","year":"2016","journal-title":"Forensic Sci Int"},{"key":"2022020118392880900_B6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1053\/comp.2002.35912","article-title":"Suicide attempts in high-dose benzodiazepine users","volume":"43","author":"Lekka","year":"2002","journal-title":"Compr Psychiatry"},{"key":"2022020118392880900_B7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/15563650701586397","article-title":"Reliability of self-reported use of amphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, and opiates among acutely hospitalized elderly medical patients","volume":"46","author":"Glintborg","year":"2008","journal-title":"Clin Toxicol"},{"key":"2022020118392880900_B8","first-page":"705","article-title":"Emergency department visits involving nonmedical use of selected prescription drugs\u2013United States, 2004\u20132008","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2022020118392880900_B9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3810\/pgm.2013.07.2684","article-title":"Risks, management, and monitoring of combination opioid, benzodiazepines, and\/or alcohol use","volume":"125","author":"Gudin","year":"2013","journal-title":"Postgrad Med"},{"key":"2022020118392880900_B10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-4939-3252-8_24","article-title":"Quantitative multidrug pain medication testing by liquid chromatography: tandem mass spectrometry (LC-MS\/MS)","volume":"1383","author":"Bodor","year":"2016","journal-title":"Methods Mol Biol"},{"key":"2022020118392880900_B11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00002508-199006000-00013","article-title":"Benzodiazepine use by chronic pain patients","volume":"6","author":"King","year":"1990","journal-title":"Clin J Pain"},{"key":"2022020118392880900_B12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/jat\/18.5.243","article-title":"Urinary screening for benzodiazepines with radioreceptor assay: comparison with EMIT d.a.u. benzodiazepine assay and high-performance liquid chromatography","volume":"18","author":"Borggaard","year":"1994","journal-title":"J Anal Toxicol"},{"key":"2022020118392880900_B13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/0076-6879(82)84037-8","article-title":"Radioimmunoassay of benzodiazepines","volume":"84","author":"Dixon","year":"1982","journal-title":"Methods Enzymol"},{"key":"2022020118392880900_B14","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/clinchem\/22.6.712","article-title":"Detection of drugs of abuse by radioimmunoassay: a summary of published data and some new information","volume":"22","author":"Cleeland","year":"1976","journal-title":"Clin Chem"},{"key":"2022020118392880900_B15","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/jat\/24.8.726","article-title":"New fluorescence polarization immunoassays for analysis of barbiturates and benzodiazepines in serum and urine: performance characteristics","volume":"24","author":"Schwenzer","year":"2000","journal-title":"J Anal Toxicol"},{"key":"2022020118392880900_B16","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/jat\/21.7.554","article-title":"The online screening technique for urinary benzodiazepines: comparison with EMIT. FPIA, and GC-MS","volume":"21","author":"Beck","year":"1997","journal-title":"J Anal Toxicol"},{"key":"2022020118392880900_B17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-227X-9-5","article-title":"Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse\/toxicology screening in emergency medicine","volume":"9","author":"Krasowski","year":"2009","journal-title":"BMC Emerg Med"},{"key":"2022020118392880900_B18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jat\/32.6.433","article-title":"Evaluation of four immunoassay screening kits for the detection of benzodiazepines in urine","volume":"32","author":"DeRienz","year":"2008","journal-title":"J Anal Toxicol"},{"key":"2022020118392880900_B19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.36076\/ppj.2010\/13\/71","article-title":"Comparison of clonazepam compliance by measurement of urinary concentration by immunoassay and LC-MS\/MS in pain management population","volume":"13","author":"West","year":"2010","journal-title":"Pain Physician"},{"key":"2022020118392880900_B20","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.5858\/2006-130-1600c-FUIALO","article-title":"False-negative urine immunoassay after lorazepam overdose","volume":"130","author":"Wenk","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"2022020118392880900_B21","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.cca.2012.03.017","article-title":"Therapeutic monitoring of benzodiazepines in the management of pain: current limitations of point of care immunoassays suggest testing by mass spectrometry to assure accuracy and improve patient safety","volume":"413","author":"Mikel","year":"2012","journal-title":"Clin Chim Acta"},{"key":"2022020118392880900_B22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/jat\/bkv140","article-title":"Comparison of LC-MS-MS and GC-MS analysis of benzodiazepine compounds included in the drug demand reduction urinalysis program","volume":"40","author":"Perez","year":"2016","journal-title":"J Anal Toxicol"},{"key":"2022020118392880900_B23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/bms.1200110607","article-title":"The decomposition of benzodiazepines during analysis by capillary gas chromatography\/mass spectrometry","volume":"11","author":"Joyce","year":"1984","journal-title":"Biomed Mass Spectrom"},{"key":"2022020118392880900_B24","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1111\/pme.12207","article-title":"Optimizing urine drug testing for monitoring medication compliance in pain management","volume":"14","author":"Melanson","year":"2013","journal-title":"Pain Med"},{"key":"2022020118392880900_B25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-1-60761-459-3_9","article-title":"LC-MS\/MS analysis of 13 benzodiazepines and metabolites in urine, serum, plasma, and meconium","volume":"603","author":"Marin","year":"2010","journal-title":"Methods Mol Biol"},{"key":"2022020118392880900_B26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.kjms.2016.01.007","article-title":"Simultaneous identification of abused drugs, benzodiazepines, and new psychoactive substances in urine by liquid chromatography tandem mass spectrometry","volume":"32","author":"Lee","year":"2016","journal-title":"Kaohsiung J Med Sci"},{"key":"2022020118392880900_B27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2478\/10004-1254-61-2010-2058","article-title":"Determination of benzodiazepines in urine via benzophenone derivatives using liquid chromatography-tandem mass spectrometry","volume":"61","author":"Roskar","year":"2010","journal-title":"Arh Hig Rada Toksikol"},{"key":"2022020118392880900_B28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0731-7085(98)00266-0","article-title":"Comparison of different immunoassays and GC-MS screening of benzodiazepines in urine","volume":"18","author":"Augsburger","year":"1998","journal-title":"J Pharm Biomed Anal"},{"key":"2022020118392880900_B29","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jchromb.2017.04.008","article-title":"Ultrasound-assisted low-density solvent dispersive liquid-liquid microextraction for the determination of 4 designer benzodiazepines in urine samples by gas chromatography-triple quadrupole mass spectrometry","volume":"1053","author":"Meng","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2022020118392880900_B30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jat\/21.5.335","article-title":"A sensitive GC-MS procedure for the analysis of flunitrazepam and its metabolites in urine","volume":"21","author":"el Sohly","year":"1997","journal-title":"J Anal Toxicol"},{"key":"2022020118392880900_B31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jchromb.2012.06.012","article-title":"Direct urine analysis for the identification and quantification of selected benzodiazepines for toxicology screening","volume":"902","author":"Karampela","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2022020118392880900_B32","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/dta.2243","article-title":"Human urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry","volume":"10","author":"Pettersson Bergstrand","year":"2018","journal-title":"Drug Test Anal"},{"key":"2022020118392880900_B33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1258\/acb.2009.009172","article-title":"Measurement of benzodiazepines in urine by liquid chromatography-tandem mass spectrometry: confirmation of samples screened by immunoassay","volume":"47","author":"Glover","year":"2010","journal-title":"Ann Clin Biochem"},{"key":"2022020118392880900_B34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-61779-934-1_4","article-title":"Benzodiazepines and metabolites from biological fluids by liquid chromatography electrospray tandem mass spectrometry","volume":"902","author":"Morris-Kukoski","year":"2012","journal-title":"Methods Mol Biol"},{"key":"2022020118392880900_B35","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/bmc.1178","article-title":"A highly sensitive method for the determination of 7-aminonitrazepam, a metabolite of nitrazepam, in human urine using high-performance electrospray liquid chromatography tandem mass spectrometry","volume":"23","author":"Kuang","year":"2009","journal-title":"Biomed Chromatogr"},{"key":"2022020118392880900_B36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jchromb.2016.08.047","article-title":"Development and application of a multi-component LC-MS\/MS method for determination of designer benzodiazepines in urine","volume":"1035","author":"Pettersson Bergstrand","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2022020118392880900_B37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchromb.2017.08.023","article-title":"An atmospheric pressure chemical ionisation liquid chromatographic-tandem mass spectrometry method for the analysis of benzodiazepines in urine","volume":"1064","author":"Dunlop","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2022020118392880900_B38","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jat\/31.7.359","article-title":"Simultaneous determination of multiple drugs of abuse and relevant metabolites in urine by LC-MS-MS","volume":"31","author":"Feng","year":"2007","journal-title":"J Anal Toxicol"},{"key":"2022020118392880900_B39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/jat\/bku083","article-title":"Rapid enzymatic hydrolysis using a novel recombinant beta-glucuronidase in benzodiazepine urinalysis","volume":"38","author":"Morris","year":"2014","journal-title":"J Anal Toxicol"},{"key":"2022020118392880900_B40","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1526-4637.2012.01350.x","article-title":"Interpretation of urine drug testing in pain patients","volume":"13","author":"Pesce","year":"2012","journal-title":"Pain Med"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/3\/3\/397\/42353809\/3_3_3_397.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/3\/3\/397\/42353809\/3_3_3_397.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T18:58:18Z","timestamp":1643741898000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/3\/3\/397\/5603108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,11,1]]},"published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1373\/jalm.2018.026658","relation":{},"ISSN":["2576-9456","2475-7241"],"issn-type":[{"value":"2576-9456","type":"print"},{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11,1]]},"published":{"date-parts":[[2018,11,1]]}}}